These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33893877)

  • 21. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection.
    Arnold EA; Hazelton P; Lane T; Christopoulos KA; Galindo GR; Steward WT; Morin SF
    PLoS One; 2012; 7(7):e40603. PubMed ID: 22792384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya.
    Odoyo JB; Morton JF; Ngure K; O'Malley G; Mugwanya KK; Irungu E; Awuor M; Dolla A; Ongolly F; Bukusi EA; Mugo NR; Baeten JM;
    J Int AIDS Soc; 2019 Jul; 22 Suppl 3(Suppl Suppl 3):e25303. PubMed ID: 31321911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
    Haberer JE; Bukusi EA; Mugo NR; Pyra M; Kiptinness C; Oware K; Garrison LE; Thomas KK; Musinguzi N; Morrison S; Anderson PL; Ngure K; Baeten JM;
    Lancet HIV; 2021 Mar; 8(3):e130-e137. PubMed ID: 33662265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
    Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
    Gandhi M; Wang G; King R; Rodrigues WC; Vincent M; Glidden DV; Cressey TR; Bacchetti P; Spinelli MA; Okochi H; Siriprakaisil O; Klinbuayaem V; Mugo NR; Ngure K; Drain PK; Baeten JM
    AIDS; 2020 Feb; 34(2):255-260. PubMed ID: 31634188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-exposure prophylaxis for transgender women and men who have sex with men: qualitative insights from healthcare providers, community organization-based leadership and end users in coastal Kenya.
    Kimani M; Sanders EJ; Chirro O; Mukuria N; Mahmoud S; Rinke de Wit TF; Graham SM; Operario D; van der Elst EM
    Int Health; 2022 May; 14(3):288-294. PubMed ID: 34325469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya.
    Jackson-Gibson M; Ezema AU; Orero W; Were I; Ohiomoba RO; Mbullo PO; Hirschhorn LR
    BMC Public Health; 2021 Jul; 21(1):1284. PubMed ID: 34210288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
    Lahuerta M; Zerbe A; Baggaley R; Falcao J; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):343-347. PubMed ID: 28777264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provider perspectives on service delivery modifications to maintain access to HIV pre-exposure prophylaxis during the COVID-19 pandemic: qualitative results from a PrEP implementation project in Kenya.
    Velloza J; Roche SD; Owidi EJ; Irungu EM; Dollah A; Kwach B; Thuo NB; Morton JF; Mugo N; Bukusi EA; O'Malley G; Ngure K; Baeten JM; Mugwanya KK;
    J Int AIDS Soc; 2023 Feb; 26(2):e26055. PubMed ID: 36739603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation.
    Ortblad KF; Mogere P; Roche S; Kamolloh K; Odoyo J; Irungu E; Mugo NR; Pintye J; Baeten JM; Bukusi E; Ngure K;
    BMC Health Serv Res; 2020 Nov; 20(1):1034. PubMed ID: 33176785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention.
    Spinelli M; Gandhi M
    Expert Rev Mol Diagn; 2024 Mar; 24(3):169-175. PubMed ID: 38353417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
    van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.